Northern Trust Corp lifted its holdings in OptiNose Inc (NASDAQ:OPTN) by 137.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 187,771 shares of the company’s stock after purchasing an additional 108,699 shares during the period. Northern Trust Corp’s holdings in OptiNose were worth $5,254,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Thompson Davis & CO. Inc. purchased a new position in shares of OptiNose in the 2nd quarter valued at about $105,000. Summit Trail Advisors LLC purchased a new position in shares of OptiNose in the 2nd quarter valued at about $109,000. Rhumbline Advisers purchased a new position in shares of OptiNose in the 2nd quarter valued at about $417,000. State of Wisconsin Investment Board purchased a new position in shares of OptiNose in the 2nd quarter valued at about $464,000. Finally, Swiss National Bank purchased a new position in shares of OptiNose in the 2nd quarter valued at about $554,000. Hedge funds and other institutional investors own 47.81% of the company’s stock.

OPTN stock opened at $9.91 on Tuesday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 10.13 and a current ratio of 10.44. OptiNose Inc has a 12-month low of $9.78 and a 12-month high of $30.00. The stock has a market capitalization of $425.47 million and a P/E ratio of -1.76.

OptiNose (NASDAQ:OPTN) last posted its quarterly earnings data on Tuesday, November 13th. The company reported ($0.61) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.72) by $0.11. The firm had revenue of $1.90 million during the quarter, compared to analyst estimates of $1.57 million. As a group, analysts expect that OptiNose Inc will post -2.93 earnings per share for the current year.

Several equities analysts recently weighed in on the company. Cantor Fitzgerald assumed coverage on OptiNose in a research note on Tuesday, August 7th. They issued an “overweight” rating and a $30.00 price target for the company. Zacks Investment Research lowered OptiNose from a “buy” rating to a “hold” rating in a research note on Wednesday, August 15th. Piper Jaffray Companies set a $30.00 price target on OptiNose and gave the company a “buy” rating in a research note on Tuesday, August 14th. Finally, BMO Capital Markets cut their price target on OptiNose from $30.00 to $28.00 and set an “outperform” rating for the company in a research note on Wednesday, August 15th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $28.75.

ILLEGAL ACTIVITY NOTICE: “OptiNose Inc (OPTN) Position Boosted by Northern Trust Corp” was first posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.dailypolitical.com/2018/11/20/optinose-inc-optn-position-boosted-by-northern-trust-corp.html.

OptiNose Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.

Read More: Asset Allocation

Want to see what other hedge funds are holding OPTN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OptiNose Inc (NASDAQ:OPTN).

Institutional Ownership by Quarter for OptiNose (NASDAQ:OPTN)

Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.